Charles Schwab
RCKT icon

Charles Schwab’s Rocket Pharmaceuticals RCKT Stock Holding History

Charles Schwab’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Buy
749,073
+24,681
+3% +$82.1K ﹤0.01% 2706
2026
Q1 		$2.59M Sell
724,392
-19,894
-3% -$79.1K ﹤0.01% 2639
2025
Q4 		$2.61M Buy
744,286
+212
+0% +$726 ﹤0.01% 2685
2025
Q3 		$2.43M Buy
744,074
+129,313
+21% +$407K ﹤0.01% 2704
2025
Q2 		$1.51M Sell
614,761
-60,720
-9% -$308K ﹤0.01% 2758
2025
Q1 		$4.51M Buy
675,481
+19,391
+3% +$192K ﹤0.01% 2312
2024
Q4 		$8.25M Buy
656,090
+86,276
+15% +$1.3M ﹤0.01% 2101
2024
Q3 		$10.5M Buy
569,814
+20,322
+4% +$416K ﹤0.01% 2001
2024
Q2 		$11.8M Buy
549,492
+16,929
+3% +$389K ﹤0.01% 1958
2024
Q1 		$14.3M Buy
532,563
+7,111
+1% +$202K ﹤0.01% 1801
2023
Q4 		$15.7M Buy
525,452
+57,246
+12% +$1.26M ﹤0.01% 1740
2023
Q3 		$9.59M Buy
468,206
+32,836
+8% +$597K ﹤0.01% 1924
2023
Q2 		$8.65M Buy
435,370
+7,851
+2% +$159K ﹤0.01% 1975
2023
Q1 		$7.32M Buy
427,519
+5,344
+1% +$105K ﹤0.01% 2020
2022
Q4 		$8.26M Buy
422,175
+78,911
+23% +$1.45M ﹤0.01% 1972
2022
Q3 		$5.48M Buy
343,264
+18,657
+6% +$291K ﹤0.01% 2167
2022
Q2 		$4.47M Buy
324,607
+1,435
+0.4% +$17.1K ﹤0.01% 2237
2022
Q1 		$5.13M Buy
323,172
+13,039
+4% +$225K ﹤0.01% 2268
2021
Q4 		$6.77M Buy
310,133
+6,829
+2% +$186K ﹤0.01% 2201
2021
Q3 		$9.07M Buy
303,304
+6,289
+2% +$229K ﹤0.01% 2066
2021
Q2 		$13.2M Buy
297,015
+15,636
+6% +$679K ﹤0.01% 1857
2021
Q1 		$12.5M Buy
281,379
+20,843
+8% +$1.14M ﹤0.01% 1830
2020
Q4 		$14.3M Buy
260,536
+26,081
+11% +$951K 0.01% 1636
2020
Q3 		$5.36M Buy
234,455
+2,449
+1% +$60.3K ﹤0.01% 2028
2020
Q2 		$4.86M Buy
232,006
+23,454
+11% +$423K ﹤0.01% 2045
2020
Q1 		$2.91M Buy
208,552
+9,219
+5% +$183K ﹤0.01% 2103
2019
Q4 		$4.54M Buy
199,333
+11,346
+6% +$189K ﹤0.01% 2068
2019
Q3 		$2.19M Buy
187,987
+2,128
+1% +$26.4K ﹤0.01% 2345
2019
Q2 		$2.79M Buy
185,859
+39,917
+27% +$697K ﹤0.01% 2251
2019
Q1 		$2.56M Buy
145,942
+15,722
+12% +$248K ﹤0.01% 2276
2018
Q4 		$1.93M Buy
130,220
+6,020
+5% +$99.9K ﹤0.01% 2345
2018
Q3 		$3.06M Buy
124,200
+81,901
+194% +$1.78M ﹤0.01% 2277
2018
Q2 		$831K Buy
+42,299
New +$800K ﹤0.01% 2639
2017
Q2 		– Sell
-6,950
Closed -$56K – 3127
2017
Q1 		$56K Hold
6,950
– – ﹤0.01% 3037
2016
Q4 		$170K Hold
6,950
– – ﹤0.01% 2992
2016
Q3 		$264K Hold
6,950
– – ﹤0.01% 2827
2016
Q2 		$207K Buy
+6,950
New +$244K ﹤0.01% 2929

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Charles Schwab's RCKT Position: Q2 2026 in Review

Charles Schwab increased its Rocket Pharmaceuticals (RCKT) stake by 3.4% in Q2 2026, buying an estimated $82.1K and bringing the position to 749,073 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2706.

Charles Schwab first reported a position in RCKT in Q2 2016 and has held it in 37 quarters since. The position peaked at $15.7M in Q4 2023. 179 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Charles Schwab held 749,073 shares of Rocket Pharmaceuticals worth $2.56M as of Q2 2026.
  • Charles Schwab bought 24,681 Rocket Pharmaceuticals shares in Q2 2026, an estimated $82.1K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2706 holding.
  • Charles Schwab first reported a position in Rocket Pharmaceuticals in Q2 2016 and has held it in 37 quarters since.
  • Charles Schwab's Rocket Pharmaceuticals position peaked at $15.7M in Q4 2023.
  • 179 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.